1.63
-0.065(-3.83%)
Currency In USD
| Previous Close | 1.7 |
| Open | 1.7 |
| Day High | 1.7 |
| Day Low | 1.59 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.12 |
| Volume | 17,338 |
| Average Volume | 71,743 |
| Market Cap | 16.58M |
| PE | -1.04 |
| EPS | -1.56 |
| Moving Average 50 Days | 1.62 |
| Moving Average 200 Days | 1.76 |
| Change | -0.07 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $5.41 as of August 18, 2025 at a share price of $1.695. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 5 years ago, it would be worth $72.81 as of August 18, 2025 at a share price of $1.695.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference
GlobeNewswire Inc.
Aug 05, 2025 12:00 PM GMT
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this yearLack of approved norovirus treatments or vaccines
Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference
GlobeNewswire Inc.
Jul 10, 2025 12:00 PM GMT
BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conferenc
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
GlobeNewswire Inc.
Jun 05, 2025 12:00 PM GMT
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHS